Scholarlink

<p>Botulinum toxin (BTX) is a neurotoxin protein produced by bacterium Clostridium botulinum. There are seven serotypes (A-G). Three formulations of serotype A (Onabotulinum, Abobotulinum, and Incobotulinum) and one formulation of serotype B (Rimabotulinum toxin) are approved by the Food and Drug Administration (FDA) for therapeutic use. In 2010, the FDA approved Onabotulinum toxin-A (ONA) as a treatment option for chronic migraine (CM) using the PREEMPT protocol, which significantly improved migraine symptoms. Due to its mechanism of action, various administration methods of ONA have been examined in several studies, showing positive effects. Additionally, differences in structure and sites of action of other formulations suggest they may also be valid options for CM treatment. This review provides an overview of the efficacy of ONA using methods other than PREEMPT, as well as the effectiveness of other BTX formulations in treating CM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Different Methods of Treatment with Onabotulinum Toxin A in Chronic Migraine and Different Types of Botulinum Toxin Used

  • 期刊论文

  • 发表日期：

    2026年7月13日

查看全文
  • Fatemeh Farham,
  • Dilara Onan,
  • Fatemeh Moghadas,
  • Paolo Martelletti

摘要

Botulinum toxin (BTX) is a neurotoxin protein produced by bacterium Clostridium botulinum. There are seven serotypes (A-G). Three formulations of serotype A (Onabotulinum, Abobotulinum, and Incobotulinum) and one formulation of serotype B (Rimabotulinum toxin) are approved by the Food and Drug Administration (FDA) for therapeutic use. In 2010, the FDA approved Onabotulinum toxin-A (ONA) as a treatment option for chronic migraine (CM) using the PREEMPT protocol, which significantly improved migraine symptoms. Due to its mechanism of action, various administration methods of ONA have been examined in several studies, showing positive effects. Additionally, differences in structure and sites of action of other formulations suggest they may also be valid options for CM treatment. This review provides an overview of the efficacy of ONA using methods other than PREEMPT, as well as the effectiveness of other BTX formulations in treating CM.